CURX · Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc. received a Nasdaq notice on May 5, 2026, granting an additional 180-day compliance period until November 2, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company had previously been notified on November 5, 2025, that its common stock closing bid price was below $1.00 for 30 consecutive business days. Nasdaq's decision to grant the extension was based on Curanex meeting all other continued listing requirements except the bid price. The company has indicated it may implement a reverse stock split to cure the deficiency. If the stock does not close at $1.00 or higher for at least 10 consecutive business days by November 2, 2026, Nasdaq will initiate delisting proceedings, which Curanex may appeal. This development is material as it directly impacts the company's listing status and access to public capital markets.